Display options
Share it on

Regen Ther. 2021 Nov 26;18:480-486. doi: 10.1016/j.reth.2021.11.001. eCollection 2021 Dec.

Fibronectin-coating enhances attachment and proliferation of mesenchymal stem cells on a polyurethane meniscal scaffold.

Regenerative therapy

Raquel Arredondo, Francesco Poggioli, Santos Martínez-Díaz, María Piera-Trilla, Raúl Torres-Claramunt, Laura Tío, Joan C Monllau

Affiliations

  1. IMIM (Hospital del Mar Medical Research Institute), C/ Dr. Aiguader 88, 08003 Barcelona, Spain.
  2. Orthopaedic Department, ICATME-Institut Universitari Quirón-Dexeus, Universitat Autònoma Barcelona, C/ Sabino de Arana 5-19, 08028 Barcelona, Spain.
  3. ASST Papa Giovanni XXIII, Piazza OMS 1, 24127 Bergamo, Italy.
  4. Orthopaedic Department, Hospital del Mar, Universitat Autònoma Barcelona, Passeig Marítim de la Barceloneta 25-29, 08003 Barcelona, Spain.

PMID: 34926733 PMCID: PMC8633527 DOI: 10.1016/j.reth.2021.11.001

Abstract

INTRODUCTION: Partial meniscectomy is one of the most common surgical strategy for a meniscal injury, but sometimes, patients complain of knee pain due to an overload in the ablated compartment. In these cases, implantation of tissue engineering scaffold could be indicated. Currently, two commercial scaffolds, based on collagen or polycaprolactone-polyurethane (PCL-PU), are available for meniscus scaffolding. In short term follow-up assessments, both showed clinical improvement and tissue formation. However, long-term studies carried out in PCL-PU showed that the new tissue decreased in volume and assumed an irregular shape. Moreover, in some cases, the scaffold was totally reabsorbed, without new tissue formation.Mesenchymal stem cells (MSCs) combined with scaffolds could represents a promising approach for treating meniscal defects because of their multipotency and self-renewal. In this work, we aimed to compare the behaviour of MSCs and chondrocytes on a PCL-PU scaffold

METHODS: We isolated rabbit bone marrow MSCs (rBM-MSCs) from two skeletally mature New Zealand white rabbits and stablished the optimum culture condition to expand them. Then, they were seeded over non-coated and FN-coated scaffolds and cultured in chondrogenic conditions. To evaluate cell functionality, we performed an MTS assay to compare cell proliferation between both conditions. Finally, a histologic study was performed to assess extracellular matrix (ECM) production in both samples, and to compare them with the ones obtained with rabbit chondrocytes (rCHs) seeded in a non-coated scaffold.

RESULTS: A culture protocol based on low FBS concentration was set as the best for rBM-MSCs expansion. The MTS assay revealed that rBM-MSCs seeded on FN-coated scaffolds have more cells on proliferation (145%; 95% CI: 107%-182%) compared with rBM-MSCs seeded on non-coated scaffolds. Finally, the histologic study demonstrated that rCHs seeded on non-coated scaffolds displayed the highest production of ECM, followed by rBM-MSCs seeded on FN-coated scaffolds. Furthermore, both cell types produced a comparable ECM pattern.

CONCLUSION: These results suggest that MSCs have low capacity attachment to PCL-PU scaffolds, but the presence of integrin alpha5beta1 (FN-receptor) in MSCs allows them to interact with the FN-coated scaffolds. These results could be applied in the design of scaffolds, and might have important clinical implications in orthopaedic surgery of meniscal injuries.

© 2021 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.

Keywords: AMT, allograft meniscus transplantation; CMI, collagen meniscal implant; ECM, extracellular matrix; FN, fibronectin; Fibronectin; ITS, Insulin Transferrin Selenium; MNCs, mononuclear cells; MSCs, mesenchymal stem cells; Meniscal injuries; Mesenchymal stem cell; PCL-PU, polycaprolactone-polyurethane; PSR, picrosirius red; Post-meniscectomy syndrome; RT, room temperature; Scaffolds; Tissue engineering; rBM, rabbit bone marrow; rCHs, rabbit chondrocytes

Conflict of interest statement

RT and SM have received funding from MBA for research projects in meniscal repair. The company is not financing the manuscript. There are no other competing interests.

References

  1. Arthroscopy. 2018 May;34(5):1621-1627 - PubMed
  2. Am J Sports Med. 2012 Apr;40(4):844-53 - PubMed
  3. Cell Transplant. 2016;25(5):829-48 - PubMed
  4. Cells Tissues Organs. 2006;184(1):1-15 - PubMed
  5. J Histochem Cytochem. 1997 Feb;45(2):307-13 - PubMed
  6. Am J Sports Med. 2011 Apr;39(4):774-82 - PubMed
  7. Cell Tissue Kinet. 1987 May;20(3):263-72 - PubMed
  8. Organogenesis. 2008 Jan;4(1):28-32 - PubMed
  9. Int J Mol Med. 2008 Mar;21(3):271-9 - PubMed
  10. Orthop Traumatol Surg Res. 2014 Dec;100(8 Suppl):S385-9 - PubMed
  11. Am J Sports Med. 2008 Oct;36(10):1978-89 - PubMed
  12. Arthroscopy. 2011 Jul;27(7):933-43 - PubMed
  13. Biomol Ther (Seoul). 2019 Jan 31;27(1):25-33 - PubMed
  14. Cartilage. 2016 Jan;7(1):29-38 - PubMed
  15. Br J Haematol. 1997 Jun;97(3):561-70 - PubMed
  16. Am J Sports Med. 2016 Oct;44(10):2615-2621 - PubMed
  17. Am J Sports Med. 2006 Jan;34(1):64-71 - PubMed
  18. J Bone Joint Surg Am. 2008 Jul;90(7):1413-26 - PubMed
  19. J Orthop Res. 2012 Jun;30(6):943-9 - PubMed
  20. Arthritis Rheum. 2005 Aug;52(8):2521-9 - PubMed
  21. Clin Orthop Relat Res. 2001 Oct;(391 Suppl):S280-94 - PubMed
  22. PLoS One. 2013 Aug 05;8(8):e70263 - PubMed
  23. Materials (Basel). 2016 Apr 07;9(4): - PubMed
  24. Rheumatology (Oxford). 2008 Aug;47(8):1137-43 - PubMed
  25. Polymers (Basel). 2020 Apr 06;12(4): - PubMed
  26. Am J Sports Med. 2010 Mar;38(3):509-19 - PubMed
  27. Stem Cell Rev Rep. 2020 Dec;16(6):1305-1315 - PubMed
  28. J Exp Orthop. 2014 Dec;1(1):12 - PubMed
  29. Osteoarthritis Cartilage. 2012 Mar;20(3):223-32 - PubMed

Publication Types